Expression of HER2/erbB-2 correlates with survival in osteosarcoma

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2781-2788

  Gorlick, Richard ^a   Huvos, Andrew G ^a   Heller, Glenn ^a   Aledo, Alex ^a   Beardsley, G Peter ^a   Healey, John H ^a   Meyers, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PROTEIN P53; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0032856174     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2781     Document Type: Article

References (33)

1. Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am 44:973-990, 1997
2. Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 10:5-15, 1992
3. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 15:76-84, 1997
4. Meyers PA, Gorlick R, Heller G, et al: Intensification of preoperative chemotherapy for osteogenic sarcoma: The results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16:2452-2458, 1998
5. Rosen G, Marcove RC, Caparros B, et al: Primary osteogenic sarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163-2177, 1979
6. Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221-1230, 1982
7. Winkler K, Beron G, Delling G, et al: Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329-337, 1988
8. Bacci G, Mercuri M, Bricolli A, et al: Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Cancer 79:245-254, 1997
9. Meyers PA, Heller G, Healey JH, et al: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11:449-453, 1993
10. Harris MB, Gieser P, Goorin AM, et al: Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group study. J Clin Oncol 16:3641-3648, 1998
11. Bieling P, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848-858, 1996
12. Taylor WF, Ivins JC, Unni KK, et al: Prognostic variables in osteosarcoma: A multi-institutional study. J Natl Cancer Inst 81:21-30, 1989
13. Baldini N, Scotlandi K, Barbanti-Brodano G, et al: Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385, 1995
14. Onda M, Matsuda S, Higaki S, et al: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78, 1996
15. Miller CW, Aslo A, Won A, et al: Alterations of the p53, Rb, and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 122:559-565, 1996
16. Toguchida J, Yamaguchi T, Ritchie B, et al: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199, 1992
17. Lonardo F, Ueda T, Huvos AG, et al: P53 and MDM2 alterations in osteosarcoma: Correlation with clinicopathologic features and proliferative rate. Cancer 79:1541-1547, 1997
18. Levesque MA, Yu H, Clark GM, et al: Enzyme-linked immuno-absorbent assay-detected p53 protein accumulation: A prognostic factor in a large breast cancer cohort. J Clin Oncol 16:2641-2650, 1998
19. Cordon-Cardo C, Sheinfeld J, Dalbagni G: Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 13:319-327, 1997
20. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 58:1149-1158, 1998
21. Ueda Y, Dockhorn-Dworniczak B, Blasius S, et al: Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119:172-178, 1993
22. Huvos AG, Rosen G, Marcove RC: Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med 101:14-18, 1977
23. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
24. Scotlandi K, Serra M, Nicoletti G, et al: Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56:2434-2439, 1996
25. Mesa-Tejada R: P-glycoprotein and multidrug resistance. N Engl J Med 334:1335-1336, 1996
26. Chan HS, Grogan TM, Haddad G, et al: P-glycoprotein expression: Critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706-1715, 1997
27. Posl M, Amling M, Grahl K, et al: P-glycoprotein expression in high grade central osteosarcoma and normal bone cells: An immunohistochemical study. Gen Diagn Pathol 142:317-325, 1997
28. Kandel RA, Campbell S, Noble-Topham S, et al: Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas: Pilot study. Diagn Mol Pathol 4:59-65, 1995
29. Andrulis IL, Bull SB, Blackstein ME, et al: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J Clin Oncol 16:1340-1349, 1998
30. Sjogren S, Inganas M, Lindgren A, et al: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998
31. Hudziak RM, Schlessinger J, Ulrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163, 1987
32. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
33. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998